Abstract 1490P
Background
Cancer is a debilitating disease that affects both patients and their caregivers. The diagnosis and treatment of cancer could affect the quality life of the patient and their family. Patients undergoing chemotherapy experience physical and emotional symptoms that affect their quality of life. Some of them experienced difficulty sleeping, depression and poor quality of life. Caregivers of cancer patients may have to cope with a variety of physical, social, and economic problems during the caregiving process. Caregivers experienced caregiver strain while providing care for the patient. The caregiver strain influences the quality of care and thus the quality of life of the patient. Hence, this study aims to determine the health-related quality of life of cancer patients on chemotherapy and its relationship with caregiver strain.
Methods
A cross sectional analytical study was conducted among cancer patients and their caregiver at the Bataan General Hospital and Medical Center. The EORTC core quality of life questionnaire (QLQ-C30) and modified caregiver strain index (MCSI) questionnaires were administered to assess HRQoL and caregiver strain respectively. Descriptive statistics, Pearson correlation and Spearman rank were performed for analysis of quality-of-life parameters and caregiver strain.
Results
A total of 145 cancer patient-caregiver dyads were included in this study. The median global health status among cancer patients was 75 (66.67 to 91.67) suggesting an optimistic view of overall health and quality of life. The median MCSI score was 19 (14 to 24) indicating a moderate to high level of strain. The relationship between health-related quality of life and caregiver strain showed minimal to no meaningful relationship.
Conclusions
Cancer patients generally exhibit satisfactory to high functioning across physical, role, and cognitive functions. The caregiving role, irrespective of the patient's condition, carries intrinsic challenges. Although the relationship between the HRQoL of patients and caregiver strain was very weak, both are important and functions independently.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1554P - Co payments in cancer patients: Analysis and estimating OOP
Presenter: Krishnamani Kalpathi
Session: Poster session 10
1555P - Estimating the social value of immuno-oncology (IO) therapies in Japan
Presenter: Tomoya Ohno
Session: Poster session 10
1556P - Current landscape of drug approvals for genitourinary (GU) cancers in North America and Europe
Presenter: Jose Tapia
Session: Poster session 10
1557P - The use of patient experience in UK NICE decision making in oncology
Presenter: Noemi Muszbek
Session: Poster session 10
1558P - Independent validation of the Breast Cancer Risk Assessment Tool (Gail model) for predicting breast cancer risk in Egyptian population
Presenter: Elaria Yacoub
Session: Poster session 10
1559P - Equity of access and clinical impact of genomic testing in patients with cancer in a UK early phase clinical trials unit
Presenter: Jonathan Poon
Session: Poster session 10
1560P - Optimal age versus real age in breast and gynaecological risk reducing surgery in BRCA1/2 carriers
Presenter: Alberta Ferrari
Session: Poster session 10
1561P - Targeted screening methodologies to select high risk individuals: LungFlag performance in Estonia Lung Cancer Screening Pilot
Presenter: Tanel Laisaar
Session: Poster session 10
1562P - The feasibility of polygenic risk score-based population screening for breast cancer: The experience from the BRIGHT study in Estonia
Presenter: Anni Lepland
Session: Poster session 10
1563P - Increasing the earlier detection of lung cancer: A toolbox for change
Presenter: Helena Wilcox
Session: Poster session 10